Takeyama Hiroshi, Wakasa Tomoko, Inoue Keisuke, Kitani Kotaro, Tsujie Masanori, Ogawa Takafumi, Yukawa Masao, Ohta Yoshio, Inoue Masatoshi
Department of Gastroenterological Surgery, Kindai University Nara Hospital, Ikoma, Nara 630-0293, Japan.
Department of Pathology, Kindai University Nara Hospital, Ikoma, Nara 630-0293, Japan.
Mol Clin Oncol. 2018 Jul;9(1):3-10. doi: 10.3892/mco.2018.1623. Epub 2018 May 10.
In patients with colorectal liver metastases (CRLM), predictive markers for response to preoperative chemotherapy are lacking. The aim of the present study was to evaluate the expression of thymidylate synthase (TS) and excision repair cross-complementation group 1 (ERCC1) as predictive markers in CRLM. A total of 24 patients with CRLM were included in this study. Tumor response was evaluated using the tumor regression grade (TRG) and Response Evaluation Criteria in Solid Tumors (RECIST) methods. TS and ERCC1 expression in paired CRLM and primary lesions were assessed by immunohistochemistry. We analyzed correlations between i) the response to preoperative chemotherapy evaluated by TRG and RECIST, ii) TS and ERCC1 expression and the response evaluated by TRG and RESICT, and iii) TS and ERCC1 expression in matched pairs of primary tumor and CRLM. The preoperative chemotherapy response evaluated by TRG and RECIST was significantly associated (P=0.0005). The response based on RECIST criteria and TRG was significantly associated with TS expression in the primary tumor (P=0.0272, and P=0.0137, respectively). No correlations were detected between marker expression in the primary tumor and in CRLM for either TS or ERCC1 (P=0.371 and P=1.00, respectively). Our data suggested that TS expression in the primary tumor is a predictive marker of preoperative chemotherapy response in CRLM based on both TRG and RECIST methods.
在结直肠癌肝转移（CRLM）患者中，缺乏术前化疗反应的预测标志物。本研究的目的是评估胸苷酸合成酶（TS）和切除修复交叉互补组1（ERCC1）作为CRLM预测标志物的表达情况。本研究共纳入24例CRLM患者。使用肿瘤退缩分级（TRG）和实体瘤疗效评价标准（RECIST）方法评估肿瘤反应。通过免疫组织化学评估配对的CRLM和原发灶中TS和ERCC1的表达。我们分析了以下各项之间的相关性：i）通过TRG和RECIST评估的术前化疗反应；ii）TS和ERCC1表达与通过TRG和RESICT评估的反应；iii）原发肿瘤和CRLM配对中的TS和ERCC1表达。通过TRG和RECIST评估的术前化疗反应显著相关（P = 0.0005）。基于RECIST标准和TRG的反应与原发肿瘤中TS的表达显著相关（分别为P = 0.0272和P = 0.0137）。对于TS或ERCC1，在原发肿瘤和CRLM中的标志物表达之间未检测到相关性（分别为P = 0.371和P = 1.00）。我们的数据表明基于TRG和RECIST方法，原发肿瘤中TS的表达是CRLM术前化疗反应的预测标志物。
